Shares of Faron Pharmaceuticals Oy (LON:FARN - Get Free Report) hit a new 52-week high during mid-day trading on Friday . The company traded as high as GBX 270 ($3.63) and last traded at GBX 250 ($3.36), with a volume of 29031 shares trading hands. The stock had previously closed at GBX 245 ($3.30).
Faron Pharmaceuticals Oy Stock Performance
The business's 50-day moving average price is GBX 217.01 and its 200-day moving average price is GBX 191.05. The company has a debt-to-equity ratio of 922.55, a quick ratio of 1.09 and a current ratio of 1.45. The stock has a market cap of £335.63 million, a P/E ratio of -6.69 and a beta of 0.36.
About Faron Pharmaceuticals Oy
(
Get Free Report)
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
Featured Articles
Before you consider Faron Pharmaceuticals Oy, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Faron Pharmaceuticals Oy wasn't on the list.
While Faron Pharmaceuticals Oy currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
